TARGOCID Powder for solution for injection, infusion or oral solution Ref.[7885] Active ingredients: Teicoplanin

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2019  Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK or trading as Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Product name and form

Targocid 200mg powder for solution for injection/infusion or oral solution.

Pharmaceutical Form

Powder for solution for injection/infusion or oral solution.

Powder for solution for injection/infusion or oral solution: spongy ivory coloured homogeneous mass.

Qualitative and quantitative composition

Each vial contains 200 mg teicoplanin equivalent to not less than 200,000 IU.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Teicoplanin

Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.

List of Excipients

Sodium chloride
Sodium hydroxide (for pH adjustment)

Pack sizes and marketing

Primary packaging:

The freeze-dried medicinal product is packaged in:

Type I, colourless glass vial of useful volume of 10 mL for 200 mg closed with bromobutyl rubber stopper and plastic flip-off top aluminium yellow overseal.

Pack sizes:

  • 1 powder vial
  • 5x1 powder vials
  • 10x1 powder vials
  • 25x1 powder vials

Not all pack sizes may be marketed.

Marketing authorization holder

Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

or trading as

Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Marketing authorization dates and numbers

PL 04425/0088

Date of first authorisation: 2 August 1989

Date of latest Renewal: 12 December 2017

Drugs

Drug Countries
TARGOCID Austria, Brazil, Estonia, Spain, Finland, France, Ireland, Japan, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.